Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Rachel Luba, Suky Martinez, Jermaine Jones, Marco Pravetoni & Sandra D Comer. (2023) Immunotherapeutic strategies for treating opioid use disorder and overdose. Expert Opinion on Investigational Drugs 32:1, pages 77-87.
Read now
Read now
Bethany Crouse, Li Zhang, Christine Robinson, Yuguang Ban, Jennifer R Vigliaturo, Sabita Roy & Marco Pravetoni. (2021) Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. Human Vaccines & Immunotherapeutics 17:11, pages 4383-4392.
Read now
Read now
R. David Heekin, Daryl Shorter & Thomas R. Kosten. (2017) Current status and future prospects for the development of substance abuse vaccines. Expert Review of Vaccines 16:11, pages 1067-1077.
Read now
Read now
Eduardo R. Butelman & Mary Jeanne Kreek. (2017) Medications for substance use disorders (SUD): emerging approaches. Expert Opinion on Emerging Drugs 22:4, pages 301-315.
Read now
Read now
Articles from other publishers (27)
Renu Poria, Deepak Kala, Rupak Nagraik, Yashika Dhir, Sunny Dhir, Bharat Singh, Naveen Kumar Kaushik, Md Salik Noorani, Ankur Kaushal & Shagun Gupta. (2024) Vaccine development: Current trends and technologies. Life Sciences 336, pages 122331.
Crossref
Crossref
James E. Barrett, Aryan Shekarabi & Saadet Inan. (2023) Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. Pharmacological Reviews 75:6, pages 1062-1118.
Crossref
Crossref
Theofanis Vavilis, Eleni Stamoula, Athanasios Sachinidis, Malamatenia Lamprinou, Ioannis Dardalas & Georgios Papazisis. (2023) Biopharmaceuticals against substance use disorders – Present and future. European Journal of Pharmacology 944, pages 175587.
Crossref
Crossref
Benedict T. Bloom & Mary-Jessimine Bushell. (2022) Vaccines against Drug Abuse—Are We There Yet?. Vaccines 10:6, pages 860.
Crossref
Crossref
Fatima A. Hamid, Cheryl L. Marker, Michael D. Raleigh, Aaron Khaimraj, Scott Winston, Paul R. Pentel & Marco Pravetoni. (2022) Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. Vaccine 40:23, pages 3244-3252.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold & Brian S. Fuehrlein. (2022) Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. Journal of the Neurological Sciences 432, pages 120094.
Crossref
Crossref
Vincent Wartenweiler, Grace Chung, Amy Stewart & Cody Wenthur. (2021) Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development. BMC Medical Ethics 22:1.
Crossref
Crossref
Jennifer A. Chandler, Jennifer Kilty & Dave Holmes. (2019) Medicalized Metamorphosis: Biological Rehabilitation of Criminal Offenders. Critical Criminology 29:3, pages 549-567.
Crossref
Crossref
April M. Huseby Kelcher, Carly A. Baehr, Fatima A. Hamid, Geoffrey T. Hart & Marco Pravetoni. (2021) Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders. The Journal of Immunology 207:3, pages 860-867.
Crossref
Crossref
Charles P. France, Gerard P. Ahern, Saadyah Averick, Alex Disney, Heather A. Enright, Babak Esmaeli‐Azad, Arianna Federico, Lisa R. Gerak, Stephen M. Husbands, Benedict Kolber, Edmond Y. Lau, Victoria Lao, David R. Maguire, Michael A. Malfatti, Girardo Martinez, Brian P. Mayer, Marco Pravetoni, Niaz Sahibzada, Phil Skolnick, Evan Y. Snyder, Nestor Tomycz, Carlos A. Valdez & Jim Zapf. (2020) Countermeasures for Preventing and Treating Opioid Overdose. Clinical Pharmacology & Therapeutics 109:3, pages 578-590.
Crossref
Crossref
Christine Robinson, Valeria Gradinati, Fatima Hamid, Carly Baehr, Bethany Crouse, Saadyah Averick, Marina Kovaliov, Danni Harris, Scott Runyon, Federico Baruffaldi, Mark LeSage, Sandra Comer & Marco Pravetoni. (2020) Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. Journal of Medicinal Chemistry 63:23, pages 14647-14667.
Crossref
Crossref
Carly Baehr, April Huseby Kelcher, Aaron Khaimraj, Dana E. Reed, Sujata G. Pandit, David AuCoin, Saadyah Averick & Marco Pravetoni. (2020) Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics 375:3, pages 469-477.
Crossref
Crossref
Morgan Brisse, Sophia M. Vrba, Natalie Kirk, Yuying Liang & Hinh Ly. (2020) Emerging Concepts and Technologies in Vaccine Development. Frontiers in Immunology 11.
Crossref
Crossref
Emily K. Dennis & Sylvie Garneau-Tsodikova. (2020) Substance use disorders: leading the road to recovery. RSC Medicinal Chemistry 11:7, pages 741-744.
Crossref
Crossref
Virgil Schijns, Alberto Fernández‐Tejada, Žarko Barjaktarović, Ilias Bouzalas, Jens Brimnes, Sergey Chernysh, Sveinbjorn Gizurarson, Ihsan Gursel, Žiga Jakopin, Maria Lawrenz, Cristina Nativi, Stephane Paul, Gabriel Kristian Pedersen, Camillo Rosano, Ane Ruiz‐de‐Angulo, Bram Slütter, Aneesh Thakur, Dennis Christensen & Ed C. Lavelle. (2020) Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunological Reviews 296:1, pages 169-190.
Crossref
Crossref
David T. Yeung, Kristopher J. Bough, Jill R. Harper & Gennady E. PlatoffJr.Jr.. (2019) National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)—August 6/7, 2019. Journal of Medical Toxicology 16:1, pages 87-105.
Crossref
Crossref
Fang Yang & Thomas R. Kosten. (2019) Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists. Psychopharmacology 236:10, pages 2899-2907.
Crossref
Crossref
Candy S. Hwang, Lauren C. Smith, Cody J. Wenthur, Beverly Ellis, Bin Zhou & Kim D. Janda. (2019) Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences. Vaccine 37:30, pages 4155-4163.
Crossref
Crossref
F. Baruffaldi, M. D. Raleigh, S. J. King, M. J. Roslawski, A. K. Birnbaum, C. Hassler, F. I. Carroll, S. P. Runyon, S. Winston, P. R. Pentel & M. Pravetoni. (2019) Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation. Molecular Pharmaceutics 16:6, pages 2364-2375.
Crossref
Crossref
David F. Zeigler, Richard Roque & Christopher H. Clegg. (2019) Optimization of a multivalent peptide vaccine for nicotine addiction. Vaccine 37:12, pages 1584-1590.
Crossref
Crossref
Hichem Moulahoum, Figen Zihnioglu, Suna Timur & Hakan Coskunol. (2019) Novel technologies in detection, treatment and prevention of substance use disorders. Journal of Food and Drug Analysis 27:1, pages 22-31.
Crossref
Crossref
Esther Blessing, Sanya Virani & John Rotrosen. 2020. Substance Use Disorders. Substance Use Disorders
167
202
.
M. A. Myagkova & V. S. Morozova. (2018) Vaccines for substance abuse treatment: new approaches in the immunotherapy of addictions. Russian Chemical Bulletin 67:10, pages 1781-1793.
Crossref
Crossref
S. Barbosa Méndez & A. Salazar-Juárez. (2018) Current status of nicotine vaccines: A narrative review. Vacunas (English Edition) 19:2, pages 67-78.
Crossref
Crossref
S. Barbosa Méndez & A. Salazar-Juárez. (2018) Estado actual de las vacunas contra la nicotina: una revisión narrativa. Vacunas 19:2, pages 67-78.
Crossref
Crossref
Megan Laudenbach, Federico Baruffaldi, Christine Robinson, Philipp Carter, Davis Seelig, Carly Baehr & Marco Pravetoni. (2018) Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports 8:1.
Crossref
Crossref
Pooja Patnaik Kuppili, Harshini Manohar & Vikas Menon. (2018) Current status of vaccines in psychiatry—A narrative review. Asian Journal of Psychiatry 31, pages 112-120.
Crossref
Crossref